Skip to content

A randomized controlled study on the application of intelligent optimized mindfulness cognitive therapy in hospitalized patients with schizophrenia

A randomized controlled study on the application of intelligent optimized mindfulness cognitive therapy in hospitalized patients with schizophrenia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093778
Enrollment
Unknown
Registered
2024-12-11
Start date
2024-12-11
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Intervention group:Conventional treatment + optimized four-week mindfulness-based cognitive therapy virtual reality technology
Control group 1:Conventional medication + physical/rehabilitation therapy + health education
Control group 2:Watch news videos in VR

Sponsors

Guangzhou Medical University Affiliated Brain Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (a) Age 18-65 years; (b) diagnosis of schizophrenia based on the diagnostic criteria of the International Classification of Diseases, 10th Edition (ICD-10); (c) The Positive and Negative Syndrome Scale (PANSS) has a score of 1-2 for "uncooperative", suggesting that the patient is able to cooperate with mindfulness therapy; (d) The Patient Health Questionnaire-9 item (PHQ-9) >=5 points, indicating that the patient has mild depression; or the Generalized Anxiety Disorder 7-item Scale (GAD-7) >=5, indicating that the patient has mild anxiety; (e) Primary school education or above, normal intelligence, and the ability to complete the scale assessment independently; (f) Signed informed consent.

Exclusion criteria

Exclusion criteria: (a) Those with serious medical diseases (e.g. eye diseases), personality disorders, alcohol or drug dependence; (b) Those who are accompanied by impulsive behavior and poor contact; (c) pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Self evaluation and other evaluation scales for depression and anxiety.;

Secondary

MeasureTime frame
Mindfulness five factors;Sleep quality;Stigma ;Self-management ability, quality of life;Positive and negative symptom scale scores;Changes in neural signals (such as brainwaves and heart rate variability).;

Countries

China

Contacts

Public ContactHaiyan Li

Guangzhou Medical University Affiliated Brain Hospital

plhocean@163.com+86 150 1848 5780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026